3SBio's shares surged 32% to 19.18 Hong Kong dollars, equivalent to US$2.45, on Tuesday after the Chinese company said it would receive an upfront payment of US$1.25 billion and potential milestone ...

Global pharmaceutical giant Eli Lilly & Co. is seeking tax incentives for a potential 236-acre biomanufacturing plant in ...

DB-OTO, which Regeneron obtained from the 2023 acquisition of Decibel Therapeutics for $109 million, works by delivering a ...

BioMarin sees growth from Voxzogo but faces competition and product declines. Market pressures lead to a downgrade from Buy ...

The deal “fits like a glove” for BioMarin’s business, according to an analyst who also thinks there could be a “valuable” ...

Over Lars Fruergaard Jørgensen's eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company ...

Biomarin Pharmaceutical BMRN underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below summarizes their recent ratings ...

San Rafael, CA-based BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for life-threatening severe medical conditions, mainly for children. BMRN is a #3 ...

Shares of BBIO stock opened at $38.57 on Wednesday. BridgeBio Pharma has a 12 month low of $21.62 and a 12 month high of $39.54. The stock has a market cap of $7.32 billion, a P/E ratio of -13.53 ...

BioMarin Pharmaceutical BMRN reported first-quarter 2025 adjusted earnings per share of $1.13, which beat the Zacks Consensus Estimate of 94 cents. Quarterly earnings rose 59% year over year, driven ...

with additional milestone and royalty potential Agreement signed with Holling Bio-Pharma Corp. ("Holling”) to commercialize daridorexant, a dual orexin receptor antagonist, for sleep disorders in ...